# Pediatric Oncology & Palliative Symptom Care: Clinical Cannabinoid Guide | CĒD Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pediatrics/cancer/ > **Published:** 2026-09-27T18:12:27-04:00 | **Last Modified / Clinically Audited:** 2026-10-15T22:09:15-04:00 > **Clinical Summary:** Home › Pediatric Cannabinoid Medicine › Medical Cannabis in Pediatric Oncology & Palliative Symptom Care Oncology & Palliative Care PEDIATRIC ONCOLOGY & PALLIATIVE SUPPORT Medical Cannabis in Pediatric Oncology & Palliative Symptom Care Childhood cancer treatments impose immense physical and emotional burdens on young patients and their families. When conventional antiemetics and analgesics fail to […] --- [Home](https://cedclinic.com/) › [Pediatric Cannabinoid Medicine](https://cedclinic.com/pediatrics/) › [Medical Cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) in Pediatric Oncology & Palliative Symptom Care Oncology & Palliative Care PEDIATRIC ONCOLOGY & PALLIATIVE SUPPORT Table of Contents - [Medical Cannabis in Pediatric Oncology & Palliative Symptom Care](#Medical_Cannabis_in_Pediatric_Oncology_038_Palliative_Symptom_Care)[When Is Cannabinoid Therapy Appropriate in Pediatric Oncology?](#When_Is_Cannabinoid_Therapy_Appropriate_in_Pediatric_Oncology) - [The Scope of Oncologic Symptom Burden in Children](#The_Scope_of_Oncologic_Symptom_Burden_in_Children) - [The Scientific Role of Cannabinoids in Pediatric Palliative Relief](#The_Scientific_Role_of_Cannabinoids_in_Pediatric_Palliative_Relief) - [Mandatory Oncologic Collaboration & Strict Purity Controls](#Mandatory_Oncologic_Collaboration_038_Strict_Purity_Controls)[Need Expert Clinical Guidance for Your Child?](#Need_Expert_Clinical_Guidance_for_Your_Child) # Medical Cannabis in Pediatric Oncology & Palliative Symptom Care Childhood cancer treatments impose immense physical and emotional burdens on young patients and their families. When conventional antiemetics and analgesics fail to manage chemotherapy-induced nausea, profound appetite loss, and intractable pain, specialized cannabinoid medicine provides compassionate, evidence-grounded palliative symptom relief. Clinical Director: **Benjamin Caplan, MD** Clinical Standard: **Refractory / Treatment-Resistant Cases Only** Oversight: **Frequent Physician Monitoring** ### When Is Cannabinoid Therapy Appropriate in Pediatric Oncology? **Clinical Appropriateness Standard:** Cannabinoids are utilized as integrative palliative symptom support for pediatric cancer patients undergoing chemotherapy, radiation, or surgical oncologic treatments who suffer from severe chemotherapy-induced nausea and vomiting (CINV), cachexia, neuropathic pain, or severe insomnia that has not yielded to frontline medications (such as Ondansetron, Aprepitant, or opioids)—or where opioid side effects cause severe constipation and distress. ## The Scope of Oncologic Symptom Burden in Children Direct Clinical Summary: Pediatric Cannabinoid Co-Management Pediatric cannabinoid care is strictly restricted to treatment-resistant conditions, including severe pediatric epilepsy and intractable autism spectrum dysregulation. Safe therapy requires weight-based milligram-per-kilogram dosing, collaborative co-management alongside the primary pediatrician and neurologist, and regular laboratory surveillance of hepatic enzymes. **Physician Source:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Board-Certified Family Physician • CED Clinic Modern pediatric oncology achieves remarkable cure rates, but the treatment protocols can be profoundly punishing. Common refractory challenges include: - **Refractory Chemotherapy-Induced Nausea & Vomiting (CINV):** Anticipatory and delayed nausea that persists despite maximal triple-antiemetic regimens, preventing hydration and oral nutrition. - **Severe Anorexia & Cachexia:** Profound nutritional decline, muscle wasting, and food aversion requiring nasogastric or gastrostomy feeding tubes. - **Neuropathic & Visceral Cancer Pain:** Vincristine-induced peripheral neuropathy, radiation mucositis, and deep bone pain that often require escalating opioid doses with devastating constipating side effects. ## The Scientific Role of Cannabinoids in Pediatric Palliative Relief Cannabinoids possess unique multimodal pharmacology that addresses multiple oncologic symptoms simultaneously: - **5-HT3 Antagonism & Brainstem Nausea Centers:** Cannabinoids act directly on the dorsal vagal complex and chemoreceptor trigger zone to suppress both acute and delayed nausea reflexes. - **Appetite Stimulation via Ghrelin & Hypothalamic Signaling:** Targeted micro-doses of full-spectrum cannabinoids stimulate hypothalamic hunger signaling and oral intake, helping children maintain caloric intake and weight. - **Opioid-Sparing Analgesia:** Co-administering cannabinoids with prescribed pain medications enhances analgesia through synergistic receptor interactions, frequently allowing clinical oncologists to reduce opioid requirements by 30% to 50%. ## Mandatory Oncologic Collaboration & Strict Purity Controls Pediatric cancer care requires absolute precision. CĒD Clinic operates in direct, transparent communication with the child’s primary pediatric oncologist at institutions like Boston Children’s Hospital and Dana-Farber. Every product undergoes strict third-party purity testing to guarantee zero microbial, fungal, or chemical impurities that could compromise an immunocompromised child. The CĒD Clinic Clinical Process for Pediatric Patients Cannabinoid medicine is never casual or one-size-fits-all. Every pediatric patient undergoes structured, conservative physician oversight to ensure maximum safety, legal protection, and clinical efficacy. 1 Comprehensive Intake & Records Review We conduct a meticulous review of prior diagnostic evaluations, failed medications, laboratory work, and specialist records. We verify refractory criteria and screen for CYP450 drug-drug interactions. 2 Customized Care Plan & Product Guidance Dr. Caplan formulates an individualized botanical care plan specifying exact cannabinoid ratios (CBD, CBDA, CBG, CBC), administration routes, and verified, third-party lab-tested (COA) products. 3 Conservative Micro-Titration Protocol Therapy begins at low, sub-therapeutic micro-doses. Families log daily symptom metrics using our clinic tracking journals, adjusting dosages gradually every 7 to 14 days under physician supervision. 4 Frequent Oversight & Team Coordination We provide frequent follow-ups, adjust formulations as the child grows, and communicate directly with your child’s primary care pediatrician, neurologist, or psychiatrist to ensure coordinated care. #### Need Expert Clinical Guidance for Your Child? Schedule a confidential consultation to explore whether [cannabinoid therapy](https://cedclinic.com/cbd-gummies-libido-enhancement/) is appropriate for your family. [Schedule Consultation](https://cedclinic.com/contact/) [← Return to Pediatrics Overview](https://cedclinic.com/pediatrics/) --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).